OXYCODONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oxycodone Hydrochloride, and when can generic versions of Oxycodone Hydrochloride launch?
Oxycodone Hydrochloride is a drug marketed by Ani Pharms, Avanthi Inc, Dr Reddys Labs Sa, Genus Lifesciences, Lannett Co Inc, Novel Labs Inc, Abhai Llc, Alkem Labs Ltd, Ascent Pharms Inc, Aurolife Pharma Llc, Chartwell Molecular, Hikma, Pharm Assoc, Quagen, Rhodes Pharms, Specgx Llc, Vistapharm, Vistapharm Llc, Wes Pharma Inc, Xttrium Labs Inc, Actavis Elizabeth, Alvogen, Amneal Pharms, Epic Pharma Llc, Nesher Pharms, Nuvo Pharm, Strides Pharma, Sun Pharm Inds Inc, Endo Operations, Barr Labs Inc, and Watson Labs. and is included in fifty-one NDAs.
The generic ingredient in OXYCODONE HYDROCHLORIDE is ibuprofen; oxycodone hydrochloride. There are sixty-four drug master file entries for this compound. Additional details are available on the ibuprofen; oxycodone hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXYCODONE HYDROCHLORIDE?
- What are the global sales for OXYCODONE HYDROCHLORIDE?
- What is Average Wholesale Price for OXYCODONE HYDROCHLORIDE?
Summary for OXYCODONE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 31 |
NDAs: | 51 |
Finished Product Suppliers / Packagers: | 38 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Clinical Trials: | 575 |
Patent Applications: | 2,337 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OXYCODONE HYDROCHLORIDE |
What excipients (inactive ingredients) are in OXYCODONE HYDROCHLORIDE? | OXYCODONE HYDROCHLORIDE excipients list |
DailyMed Link: | OXYCODONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for OXYCODONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Henry Ford Health System | Phase 4 |
University of Miami | Phase 3 |
Murdoch Childrens Research Institute | Phase 4 |
Pharmacology for OXYCODONE HYDROCHLORIDE
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for OXYCODONE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for OXYCODONE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OXAYDO | Tablets | oxycodone hydrochloride | 5 mg and 7.5 mg | 202080 | 1 | 2012-02-07 |
OXYCONTIN | Extended-release Tablets | oxycodone hydrochloride | 20 mg | 022272 | 2 | 2010-10-29 |
OXYCONTIN | Extended-release Tablets | oxycodone hydrochloride | 15 mg | 022272 | 1 | 2010-10-28 |
OXYCONTIN | Extended-release Tablets | oxycodone hydrochloride | 10 mg | 022272 | 1 | 2010-10-25 |
OXYCONTIN | Extended-release Tablets | oxycodone hydrochloride | 30 mg, 60 mg and 80 mg | 022272 | 1 | 2010-10-18 |
OXYCONTIN | Extended-release Tablets | oxycodone hydrochloride | 40 mg | 022272 | 1 | 2010-10-04 |
US Patents and Regulatory Information for OXYCODONE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting OXYCODONE HYDROCHLORIDE
ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nesher Pharms | OXYCODONE HYDROCHLORIDE | oxycodone hydrochloride | TABLET;ORAL | 077290-001 | Dec 8, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Strides Pharma | OXYCODONE HYDROCHLORIDE | oxycodone hydrochloride | TABLET;ORAL | 077712-002 | Jan 31, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Alvogen | OXYCODONE HYDROCHLORIDE | oxycodone hydrochloride | TABLET;ORAL | 202116-001 | Dec 30, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Specgx Llc | OXYCODONE HYDROCHLORIDE | oxycodone hydrochloride | SOLUTION;ORAL | 210758-002 | Apr 30, 2018 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |